Last reviewed · How we verify
HS-20004
At a glance
| Generic name | HS-20004 |
|---|---|
| Also known as | Noiiglutide Injection |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects. (PHASE2)
- Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic Patients (PHASE1)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Volunteers (PHASE1)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-20004 CI brief — competitive landscape report
- HS-20004 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI